Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Maria Chaudhry, Raphael Steiner, Catherine Claussen, Krina Patel, Hans Lee, Donna Weber, Sheeba Thomas, Chun Feng, Behrang Amini, Robert Orlowski, Lei Feng & Elisabet E. Manasanch. (2019) Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström’s macroglobulinemia. Leukemia & Lymphoma 60:4, pages 964-970.
Read now
Read now
Articles from other publishers (13)
Giulia Mingrone, Anna Astarita, Anna Colomba, Cinzia Catarinella, Marco Cesareo, Lorenzo Airale, Arianna Paladino, Dario Leone, Fabrizio Vallelonga, Sara Bringhen, Francesca Gay, Franco Veglio & Alberto Milan. (2023) Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience. Cancers 15:4, pages 1149.
Crossref
Crossref
Simona Camero, Matteo Cassandri, Silvia Pomella, Luisa Milazzo, Francesca Vulcano, Antonella Porrazzo, Giovanni Barillari, Cinzia Marchese, Silvia Codenotti, Miriam Tomaciello, Rossella Rota, Alessandro Fanzani, Francesca Megiorni & Francesco Marampon. (2022) Radioresistance in rhabdomyosarcomas: Much more than a question of dose. Frontiers in Oncology 12.
Crossref
Crossref
Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-ichi Fuchida, Aya Nakaya, Tomoki Itou, Ryosuke Yamamura, Hirokazu Tanaka, Hirohiko Shibayama, Yutaka Shimazu, Hitoji Uchiyama, Satoshi Yoshihara, Yoko Adachi, Mitsuhiro Matsuda, Hitoshi Hanamoto, Nobuhiko Uoshima, Satoru Kosugi, Kensuke Ohta, Hideo Yagi, Yuzuru Kanakura, Itaru Matsumura, Masayuki Hino, Shosaku Nomura, Chihiro Shimazaki, Akifumi Takaori-Kondo & Junya Kuroda. (2022) Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. Therapeutic Advances in Hematology 13, pages 204062072211045.
Crossref
Crossref
Giulia Mingrone, Anna Astarita, Lorenzo Airale, Ilaria Maffei, Marco Cesareo, Teresa Crea, Giulia Bruno, Dario Leone, Eleonora Avenatti, Cinzia Catarinella, Marco Salvini, Giusy Cetani, Francesca Gay, Sara Bringhen, Franco Veglio, Fabrizio Vallelonga & Alberto Milan. (2021) Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Isamu Sugiura, Kenshi Suzuki, Masaki Ri, Takaaki Chou, Naoki Takezako, Kazutaka Sunami, Tadao Ishida, Tohru Izumi, Shuji Ozaki, Yoshihisa Shumiya & Shinsuke Iida. (2019) Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. International Journal of Hematology 111:1, pages 57-64.
Crossref
Crossref
Ananya Pal, Hsin Yao Chiu & Reshma Taneja. (2019) Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeutics. Redox Biology 25, pages 101124.
Crossref
Crossref
Claudia Busonero, Stefano Leone, Stefania Bartoloni & Filippo Acconcia. (2019) Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer. Molecular and Cellular Endocrinology 480, pages 107-121.
Crossref
Crossref
Lev Litichevskiy, Ryan Peckner, Jennifer G. Abelin, Jacob K. Asiedu, Amanda L. Creech, John F. Davis, Desiree Davison, Caitlin M. Dunning, Jarrett D. Egertson, Shawn Egri, Joshua Gould, Tak Ko, Sarah A. Johnson, David L. Lahr, Daniel Lam, Zihan Liu, Nicholas J. Lyons, Xiaodong Lu, Brendan X. MacLean, Alison E. Mungenast, Adam Officer, Ted E. Natoli, Malvina Papanastasiou, Jinal Patel, Vagisha Sharma, Courtney Toder, Andrew A. Tubelli, Jennie Z. Young, Steven A. Carr, Todd R. Golub, Aravind Subramanian, Michael J. MacCoss, Li-Huei Tsai & Jacob D. Jaffe. (2018) A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. Cell Systems 6:4, pages 424-443.e7.
Crossref
Crossref
Zihua Guo, Huijun Li, Yudi Geng, Jian Cui, Ning Tang & Dengju Li. (2018) Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma. The American Journal of the Medical Sciences 355:4, pages 350-356.
Crossref
Crossref
Raphael E. Steiner, Robert Z. Orlowski & Hans C. Lee. (2018) Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient. Acta Haematologica 139:1, pages 67-70.
Crossref
Crossref
Claudia Busonero, Stefano Leone, Cinzia Klemm & Filippo Acconcia. (2018) A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells. Molecular and Cellular Endocrinology 460, pages 229-237.
Crossref
Crossref
Adriana Mañas, Wenjing Chen, Adam Nelson, Qi Yao & Jialing Xiang. (2018) BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death. Biochemical and Biophysical Research Communications 496:1, pages 18-24.
Crossref
Crossref
Claire L. Soave, Tracey Guerin, Jinbao Liu & Q. Ping Dou. (2017) Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer and Metastasis Reviews 36:4, pages 717-736.
Crossref
Crossref